The precise estimation of kidney function in patients with cancer is of great importance as deterioration and decreased kidney function are common and often kidney function-based dose adjustments of chemotherapy and other cancer-related medicines are necessary in these patients. There is an ongoing debate regarding the most suitable technique to determine kidney function based on the availability, accuracy, and validation of available glomerular filtration rate-estimating formulas in patients with cancer. Recent data suggest that cystatin-based formulas are superior to creatinine-based GFR formulas not only in the general population but also in patients with cancer.
MalyszkoJLeeMWCapassoG, et al. How to assess kidney function in oncology patients. Kidney Int2020; 97(5): 894–903.
2.
SprangersBAbudayyehALatchaS, et al. How to determine kidney function in cancer patients?Eur J Cancer2020; 132: 141–149.
3.
CasalMANolinTDBeumerJH. Estimation of kidney function in oncology: implications for anticancer drug selection and dosing. Clin J Am Soc Nephrol2019; 14(4): 587–595.
4.
McMahonBARosnerMH. GFR measurement and chemotherapy dosing in patients with kidney disease and cancer. Kidney3602020; 1(2): 141–150.
5.
LeveyASInkerLA. Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther2017; 102(3): 405–419.
6.
CapassoABenigniACapitanioU, et al. Summary of the international conference on onco-nephrology: an emerging field in medicine. Kidney Int2019; 96(3): 555–567.
7.
Launay-VacherVOudardSJanusN, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer2007; 110(6): 1376–1384.
8.
Launay-VacherVSpanoJPJanusN, et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol2009; 70(2): 124–133.
9.
JanusNLaunay-VacherVByloosE, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer2010; 103(12): 1815–1821.
10.
Launay-VacherVChatelutELichtmanSM, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol2007; 18(8): 1314–1321.
11.
Launay-VacherVEtessamiRJanusN, et al. Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung2009; 187(1): 69–74.
12.
Launay-VacherVAyllonJJanusN, et al. Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer2009; 7(3): E83–E89.
13.
Launay-VacherVJanusNDerayG. Renal insufficiency and cancer treatments. ESMO Open2016; 1(4): e000091.
14.
ChristiansenCFJohansenMBLangebergWJ, et al. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med2011; 22(4): 399–406.
15.
SoveriIBergUBBjörkJ, et al. Measuring GFR: a systematic review. Am J Kidney Dis2014; 64(3): 411–424.
16.
SteneGBHelbostadJLAmundsenT, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol2015; 54(3): 340–348.
17.
HudsonJQNolinTD. Pragmatic use of kidney function estimates for drug dosing: the tide is turning. Adv Chronic Kidney Dis2018; 25(1): 14–20.
18.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron1976; 16(1): 31–41.
19.
LeveyASCoreshJGreeneT, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med2006; 145(4): 247–254.
20.
LeveyASStevensLASchmidCH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med2009; 150(9): 604–612.
21.
JanowitzTWilliamsEHMarshallA, et al. New model for estimating glomerular filtration rate in patients with cancer. J Clin Oncol2017; 35(24): 2798–2805.
22.
StevensPELevinA. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med2013; 158(11): 825–830.
23.
WangEPaulusJKHackenyosD, et al. Imprecise kidney function thresholds in cancer clinical trials and the potential for harm. JNCI Cancer Spectr2018; 2(4): y060.
24.
InkerLASchmidCHTighiouartH, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. New Engl J Med2012; 367(1): 20–29.
25.
StevensLASchmidCHGreeneT, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int2009; 75(6): 652–660.
26.
KnightELVerhaveJCSpiegelmanD, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int2004; 65(4): 1416–1421.
27.
StevensLACoreshJSchmidCH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis2008; 51(3): 395–406.
28.
SjöströmPTidmanMJonesI. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest2005; 65(2): 111–124.
29.
HsuCYYangWParikhRV, et al. Race, genetic ancestry, and estimating kidney function in CKD. New Engl J Med2021; 385(19): 1750–1760.
30.
ShlipakMGMatsushitaKÄrnlövJ, et al. Cystatin C versus creatinine in determining risk based on kidney function. New Engl J Med2013; 369(10): 932–943.
31.
ShlipakMGSarnakMJKatzR, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. New Engl J Med2005; 352(20): 2049–2060.
32.
InkerLAEneanyaNDCoreshJ, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med2021; 385(19): 1737–1749.
33.
KimmelMBraunNAlscherMD. Influence of thyroid function on different kidney function tests. Kidney Blood Press Res2012; 35(1): 9–17.
34.
TakeuchiMFukudaYNakanoI, et al. Elevation of serum cystatin C concentrations in patients with chronic liver disease. Eur J Gastroenterol Hepatol2001; 13(8): 951–955.
35.
KosJStabucBSchweigerA, et al. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res1997; 3(10): 1815–1822.
36.
KosJStabucBCimermanN, et al. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem1998; 44(12): 2556–2557.
37.
KosJWerleBLahT, et al. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers2000; 15(1): 84–89.
38.
PageMKBükkiJLuppaP, et al. Clinical value of cystatin C determination. Clin Chim Acta2000; 297(1–2): 67–72.
39.
NakaiKKikuchiMFujimotoK, et al. Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol2008; 12(2): 132–139.
40.
BodnarLWcisloGBSmoterM, et al. Cystatin C as a parameter of glomerular filtration rate in patients with ovarian cancer. Kidney Blood Press Res2010; 33(5): 360–367.
41.
JonesMDenieffeSGriffinC, et al. Evaluation of cystatin C in malignancy and comparability of estimates of GFR in oncology patients. Pract Lab Med2017; 8: 95–104.
42.
Laurent-MathaVHuesgenPFMassonO, et al. Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment. FASEB J2012; 26(12): 5172–5181.
43.
LetoGIncorvaiaLFlandinaC, et al. Clinical impact of cystatin C/Cathepsin L and follistatin/activin A systems in breast cancer progression: A Preliminary Report. Cancer Investig2016; 34(9): 415–423.
44.
LetoGCrescimannoMFlandinaC. On the role of cystatin C in cancer progression. Life Sci2018; 202: 152–160.
45.
LetoGTumminelloFMCrescimannoM, et al. Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications. Clin Exp Metastasis2004; 21(2): 91–106.
46.
DemirtaşSAkanÖCanM, et al. Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia. Clin Biochem2006; 39(2): 115–118.
47.
VermassenTGeboesKDe ManM, et al. Neither creatinine- nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agents. Nephrol Dial Transplant2018; 33(3): 402–408.
48.
CostaESilvaVTGil LAJrInkerLA, et al. A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors. Kidney Int2022; 101(3): 607–614.
49.
EbertNShlipakMG. Cystatin C is ready for clinical use. Curr Opin Nephrol Hypertens2020; 29(6): 591–598.
50.
InkerLALeveyASCoreshJ. Estimated glomerular filtration rate from a panel of filtration markers-hope for increased accuracy beyond measured glomerular filtration rate?Adv Chronic Kidney Dis2018; 25(1): 67–75.
